Europe Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 27
1.4 LIMITATIONS 29
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 32
2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 CURRENCY AND PRICING 34
2.5 DBMR TRIPOD DATA VALIDATION MODEL 35
2.6 MULTIVARIATE MODELLING 38
2.7 PRODUCT AND SERVICES LIFELINE CURVE 38
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.9 DBMR MARKET POSITION GRID 40
2.10 MARKET END USER COVERAGE GRID 41
2.11 VENDOR SHARE ANALYSIS 42
2.12 SECONDARY SOURCES 43
2.13 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 46
4.1 PESTEL ANALYSIS 48
4.2 PORTER'S FIVE FORCES 49
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021) 50
5 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 51
6 MARKET OVERVIEW 54
6.1 DRIVERS 56
6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 56
6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 57
6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 58
6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 58

6.2 RESTRAINTS 59
6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 59
6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 59
6.3 OPPORTUNITIES 60
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 60
6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE 60
6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS 62
6.4 CHALLENGES 63
6.4.1 PRODUCT RECALLS 63
6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 63
7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES 64
7.1 OVERVIEW 65
7.2 REAGENTS & CONSUMABLES 68
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES 68
7.4 SERVICES 69
8 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 71
8.1 OVERVIEW 72
8.2 VIRAL 75
8.2.1 CORONAVIRUS 76
8.2.2 INFLUENZA VIRUS 76
8.2.3 ADENOVIRUS 76
8.2.4 RHINOVIRUS 76
8.2.5 ROTAVIRUS 76
8.2.6 OTHERS 76
8.3 BACTERIAL 77
8.3.1 PNEUMONIAE 78
8.3.2 BORDETELLA PERTUSSIS 78
8.3.3 STAPHYLOCOCCUS 78
8.3.4 OTHERS 78
8.4 PARASITES 78
8.5 FUNGAL 79

9 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 81
9.1 OVERVIEW 82
9.2 RESPIRATORY INFECTIONS 85
9.3 GASTROENTERITIS 86
9.4 SEXUALLY TRANSMITTED INFECTIONS 86
9.5 SEPSIS 87
9.6 MENINGITIS 88
9.7 OTHERS 89
10 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 91
10.1 OVERVIEW 92
10.2 RESPIRATORY PANEL 95
10.3 GI-ENTERIC PANEL 95
10.4 SEXUALLY TRANSMITTED DISEASE PANEL 96
10.5 BLOOD-SEPSIS PANEL 97
10.6 MENINGITIS PANEL 98
10.7 OTHERS 99
11 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 100
11.1 OVERVIEW 101
11.2 HOSPITALS 104
11.3 CLINICAL LABORATORIES 104
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 105
11.5 RESEARCH INSTITUTES 106
11.6 OTHERS 107
12 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION 108
12.1 EUROPE 109
12.1.1 GERMANY 116
12.1.2 U.K. 119
12.1.3 FRANCE 122
12.1.4 ITALY 125
12.1.5 SPAIN 128
12.1.6 NETHERLANDS 131
12.1.7 SWITZERLAND 134
12.1.8 RUSSIA 137
12.1.9 BELGIUM 140
12.1.10 TURKEY 143
12.1.11 REST OF EUROPE 146

13 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 147
13.1 COMPANY SHARE ANALYSIS: EUROPE 147
14 SWOT ANALYSIS 148
15 COMPANY PROFILE 149
15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMRIEUX SA) 149
15.1.1 COMPANY SNAPSHOT 149
15.1.2 REVENUE ANALYSIS 149
15.1.3 COMPANY SHARE ANALYSIS 150
15.1.4 PRODUCT PORTFOLIO 150
15.1.5 RECENT DEVELOPMENTS 151
15.2 F. HOFFMANN-LA ROCHE LTD 152
15.2.1 COMPANY SNAPSHOT 152
15.2.2 REVENUE ANALYSIS 152
15.2.3 COMPANY SHARE ANALYSIS 153
15.2.4 PRODUCT PORTFOLIO 153
15.2.5 RECENT DEVELOPMENT 154
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY 155
15.3.1 COMPANY SNAPSHOT 155
15.3.2 RECENT FINANCIALS 155
15.3.3 COMPANY SHARE ANALYSIS 156
15.3.4 PRODUCT PORTFOLIO 156
15.3.5 RECENT DEVELOPMENT 157
15.4 CEPHEID (A SUBSIDIARY OF DANAHER) 158
15.4.1 COMPANY SNAPSHOT 158
15.4.2 RECENT FINANCIALS 158
15.4.3 COMPANY SHARE ANALYSIS 159
15.4.4 PRODUCT PORTFOLIO 159
15.4.5 RECENT DEVELOPMENTS 160
15.5 QIAGEN 161
15.5.1 COMPANY SNAPSHOT 161
15.5.2 RECENT FINANCIALS 161
15.5.3 COMPANY SHARE ANALYSIS 162
15.5.4 PRODUCT PORTFOLIO 162
15.5.5 RECENT DEVELOPMENT 162

15.6 ABBOTT 163
15.6.1 COMPANY SNAPSHOT 163
15.6.2 REVENUE ANALYSIS 163
15.6.3 PRODUCT PORTFOLIO 164
15.6.4 RECENT DEVELOPMENT 164
15.7 AKONNI BIOSYSTEMS, INC. 165
15.7.1 COMPANY SNAPSHOT 165
15.7.2 PRODUCT PORTFOLIO 165
15.7.3 RECENT DEVELOPMENT 165
15.8 APPLIED BIOCODE, INC. 166
15.8.1 COMPANY SNAPSHOT 166
15.8.2 PRODUCT PORTFOLIO 166
15.8.3 RECENT DEVELOPMENTS 167
15.9 BD 168
15.9.1 COMPANY SNAPSHOT 168
15.9.2 REVENUE ANALYSIS 168
15.9.3 PRODUCT PORTFOLIO 169
15.9.4 RECENT DEVELOPMENTS 169
15.10 BIOCARTIS 170
15.10.1 COMPANY SNAPSHOT 170
15.10.2 REVENUE ANALYSIS 170
15.10.3 PRODUCT PORTFOLIO 171
15.10.4 RECENT DEVELOPMENT 171
15.11 BIO-RAD LABORATORIES, INC. 172
15.11.1 COMPANY SNAPSHOT 172
15.11.2 REVENUE ANALYSIS 172
15.11.3 PRODUCT PORTFOLIO 173
15.11.4 RECENT DEVELOPMENT 173
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 174
15.12.1 COMPANY SNAPSHOT 174
15.12.2 REVENUE ANALYSIS 174
15.12.3 PRODUCT PORTFOLIO 175
15.12.4 RECENT DEVELOPMENT 175
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.) 176
15.13.1 COMPANY SNAPSHOT 176
15.13.2 RECENT FINANCIALS 176
15.13.3 PRODUCT PORTFOLIO 177
15.13.4 RECENT DEVELOPMENTS 177

15.14 HOLOGIC, INC. 178
15.14.1 COMPANY SNAPSHOT 178
15.14.2 RECENT FINANCIALS 178
15.14.3 PRODUCT PORTFOLIO 179
15.14.4 RECENT DEVELOPMENT 179
15.15 MIRXES PTE LTD. 180
15.15.1 COMPANY SNAPSHOT 180
15.15.2 PRODUCT PORTFOLIO 180
15.15.3 RECENT DEVELOPMENT 180
15.16 NANMIX, INC. 181
15.16.1 COMPANY SNAPSHOT 181
15.16.2 PRODUCT PORTFOLIO 181
15.16.3 RECENT DEVELOPMENT 181
15.17 PROMINEX INC. 182
15.17.1 COMPANY SNAPSHOT 182
15.17.2 PRODUCT PORTFOLIO 182
15.17.3 RECENT DEVELOPMENT 182
15.18 QUANTUMDX GROUP LTD. 183
15.18.1 COMPANY SNAPSHOT 183
15.18.2 PRODUCT PORTFOLIO 183
15.18.3 RECENT DEVELOPMENTS 183
15.19 SEEGENE INC. 184
15.19.1 COMPANY SNAPSHOT 184
15.19.2 REVENUE ANALYSIS 184
15.19.3 PRODUCT PORTFOLIO 185
15.19.4 RECENT DEVELOPMENTS 188
15.20 SIEMENS HEALTHCARE GMBH 189
15.20.1 COMPANY SNAPSHOT 189
15.20.2 RECENT FINANCIALS 189
15.20.3 PRODUCT PORTFOLIO 190
15.20.4 RECENT DEVELOPMENT 190
15.21 THERMOFISHER SCIENTIFIC INC. 191
15.21.1 COMPANY SNAPSHOT 191
15.21.2 RECENT FINANCIALS 191
15.21.3 PRODUCT PORTFOLIO 192
15.21.4 RECENT DEVELOPMENT 192
16 QUESTIONNAIRE 193
17 RELATED REPORTS 196